Biotech Catalyst Daily · Archive
Every past edition. New briefings publish every weekday by 7:00 AM Eastern.
- Apr 20, 2026 Nektar's alopecia data fuels Phase 3 ambitions Nektar's promising mid-stage trial results may lead to a Phase 3 study.
- Apr 18, 2026 UCB to Acquire Neurona for Up to $1.2B in Seizure Therapy UCB's acquisition diversifies its epilepsy treatment portfolio amid rising competition.
- Apr 17, 2026 UCB Acquires Neurona for Up to $1.2B to Enhance Epilepsy Pipeline UCB's acquisition of Neurona marks a strategic move into cell therapy for epilepsy.
- Apr 12, 2026 FDA Rejects Replimune's Melanoma Drug for Second Time Replimune faces regulatory challenges as FDA denies melanoma treatment again.